UK biotech Circassia Pharmaceuticals today announced the appointment of Jonathan Emms to the newly-created role of chief operating officer (COO). 12 August 2019
US pharma major Eli Lilly announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations before markets opened this morning. 7 August 2019
Immunotherapeutics developer Imcyse today announced the appointment of seasoned biotech expert Thomas Taapken as executive chairman and chairman of the board. 5 August 2019
A month after announcing that Adrian Rawcliffe is to succeed the retiring James Noble as chief executive in September, Adaptimmune has revealed further management changes. 2 August 2019
US drugmaker Vertex Pharmaceuticals today revealed that its board has approved a planned transition of chairman, president and chief executive Dr Jeffrey Leiden, into the role of executive chairman of the board, effective April 1, 2020. 25 July 2019
Emirati company Julphar, one of the largest pharmaceutical manufacturers in the Middle East and North Africa (MENA), has announced the appointment of new executives to help guide the company towards profitability and long-term success. 22 July 2019
Julian Gilbert, the founder of Anglo-American company Acacia Pharma Group, is to step down from his role as chief executive and director at the end of the month. 18 July 2019
Gilead Sciences announced today that John McHutchison, chief scientific officer and head of R&D, has decided to leave the company, effective next month. 17 July 2019
US biotech major Gilead Sciences has lured high pharma profile Christi Shaw to the company as chief executive of CAR-T cancer therapy specialist Kite. 12 July 2019
US RNAi therapies specialist Alnylam yesterday announced that Jeff Poulton joined the company on July 11, 2019, and has been appointed executive vice president and chief financial officer (CFO), effective August 13. 12 July 2019
Privately-held German biotech firm Immatics Biotechnologies today announced that Harpreet Singh has been appointed the company’s chief executive (CEO). 8 July 2019
After the failure of its latest drug candidate in clinical trials, US oncology specialist Merrimack Pharmaceuticals has issued a document to the US Securities and Exchange Commission, announcing the departure of the company’s top two executives. 4 July 2019
French nanomedicine company Nanobiotix today announced organizational changes to align with strategic priorities post European market approval for Hensify (NBTXR3), which was cleared for marketing in April. 1 July 2019
Ever since Dr Scott Gottlieb unexpectedly stepped down as head of the US Food and Drug Administration in March this year, less than two years into his tenure, there has been speculation about where he would re-appear 28 June 2019
USA-based antibacterial products developer Entasis Therapeutics has announced the appointment of David Meek, currently chief executive of French pharma company Ipsen, as chairman of the board of directors, effective immediately. 25 June 2019
German drugmaker Stada Arzneimittel has nominated a successor for Enrique Häusermann, the long-time general manager of its Italian unit EG SpA. 20 June 2019
Valo Therapeutics, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines, has appointed Dr Michael Stein to the full-time role of chief executive, having served as part-time co-chairman since inception in January 2017. 17 June 2019
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024